Documento-Fibrosis Pulmonar
Secuelas pulmonares de COVID-19: Enfoque en la enfermedad pulmonar intersticial
Although pirfenidone slows disease progression in patients with idiopathic pulmonary fibrosis (IPF), in clinical practice, patients often cannot tolerate the recommended dose because of several adverse events. This study aimed to investigate adverse events associated with pirfenidone and factors associated with dose reduction…
Factors associated with dose reduction of pirfenidone in patients with idiopathic pulmonary fibrosis: A study based on realworld clinical data.
Although pirfenidone slows disease progression in patients with idiopathic pulmonary fibrosis (IPF), in clinical practice, patients often cannot tolerate the recommended dose because of several adverse events. This study aimed to investigate adverse events associated with pirfenidone and factors associated with dose reduction…
